IP Library Granted Patent US 7,459,569
Granted Patent B2
US 7,459,569 · App. 10/514,836 · Granted Dec 2, 2008

Method of forming iron hydroxypyrone compounds

Assignee: Vitra Pharmaceuticals Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,459,569
App. No.
10/514,836
Granted
Dec 2, 2008
Kind
B2
Abstract

A method of forming an iron hydroxypyrone compound comprising reacting an iron salt of a carboxylic acid and a hydroxypyrone in an aqueous solution at a pH greater than 7.

Claims (10)

1. A method of forming an iron hydroxypyrone compound which is a ferric hydroxypyrone complex comprising hydroxypyrone and ferric iron in the stoichiometric ratio of 3:1 hydroxypyrone: ferric iron, which comprises the step of reacting one or more iron salt of a carboxylic acid and one or more hydroxypyrone in an aqueous solution at a pH greater than 7, wherein the aqueous solution comprises one or more base selected from the group consisting of alkali metal hydroxides, sodium or potassium carbonate and mixtures thereof, wherein the carboxylic acid is selected from the group consisting of citric acid, isocitric acid, succinic acid, fumaric acid, maleic acid, malonic acid, aconitic acid, glutaric acid, tartaric acid, gluconic acid, lactic acid, and mixtures thereof, wherein the hydroxypyrone is selected from the group consisting of maltol or ethyl maltol, and mixtures thereof; and wherein the concentration of the base is from 1 to 50% by weight of the aqueous solution.

2. The method according to claim 1 , wherein the pH of the aqueous solution is greater than 9.

3. The method according to claim 1 , wherein the aqueous solution comprises one or more base selected from the group consisting of: alkali metal hydroxides and mixtures thereof.

4. The method according to claim 3 , wherein the base is sodium hydroxide.

5. The method according to claim 1 , wherein the molar ratio of hydroxypyrone to the iron salt is at least 3:1.

6. The method according to claim 1 , wherein the one or more iron salt of a carboxylic acid and the one or more hydroxypyrone are dissolved in the aqueous solution.

7. The method according to claim 1 , wherein the iron hydroxypyrone compound is ferric trimaltol.

8. The method according to claim 1 , wherein the one or more iron salt of a carboxylic acid further comprises one or more monovalent cations selected from sodium or potassium.

9. A method of forming an iron hydroxypyrone compound which is a ferric hydroxypyrone complex comprising hydroxypyrone and ferric iron in the stoichiometric ratio of 3:1 hydroxypyrone: ferric iron, which comprises the step of adding one or more iron salt of a carboxylic acid in a solid form to a solution of one or more hydroxypyrone in an aqueous solution at a pH greater than 7, wherein the aqueous solution comprises one or more base selected from the group consisting of alkali metal hydroxides, sodium or potassium carbonate and mixtures thereof, wherein the carboxylic acid is selected from the group consisting of citric acid, isocitric acid, succinic acid, fumaric acid, maleic acid, malonic acid, aconitic acid, glutaric acid, tartaric acid, gluconic acid, lactic acid, and mixtures thereof, wherein the hydroxypyrone is selected from the group consisting of maltol or ethyl maltol, and mixtures thereof; and wherein the method comprises the step of adding the one or more iron salt of a carboxylic acid in a solid form to a solution of the one or more hydroxypyrone.

10. A method of forming an iron hydroxypyrone compound which is a ferric hydroxypyrone complex comprising hydroxypyrone and ferric iron in the stoichiometric ratio of 3:1 hydroxypyrone: ferric iron, which comprises the step of mixing a solution of one or more iron salt of a carboxylic acid with a solution of one or more hydroxypyrone in an aqueous solution at a pH greater than 7, wherein the aqueous solution comprises one or more base selected from the group consisting of alkali metal hydroxides, sodium or potassium carbonate and mixtures thereof, wherein the carboxylic acid is selected from the group consisting of citric acid, isocitric acid, succinic acid, fumaric acid, maleic acid, malonic acid, aconitic acid, glutaric acid, tartaric acid, gluconic acid, lactic acid, and mixtures thereof, wherein the hydroxypyrone is selected from the group consisting of maltol or ethyl maltol, and mixtures thereof; and wherein the method comprises the step of mixing a solution of the one or more iron salt of a carboxylic acid with a solution of the one or more hydroxypyrone.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Oct 4, 2023
From: AOP HEALTH INTERNATIONAL MANAGEMENT AG
To: SHIELD TX (UK) LIMITED
Reel/Frame 065125/0610 →
SECURITY INTEREST Recorded Jan 4, 2023
From: AOP HEALTH INTERNATIONAL MANAGEMENT
To: SHIELD TX (UK) LIMITED
Reel/Frame 062273/0488 →
SECURITY INTEREST Recorded Aug 1, 2022
From: SHIELD TX (UK) LIMITED
To: AOP HEALTH INTERNATIONAL MANAGEMENT AG
Reel/Frame 060684/0447 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2019
From: IRON THERAPEUTICS AG
To: SHIELD TX (UK) LTD.
Reel/Frame 050419/0619 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2012
From: VITRA PHARMACEUTICALS LTD.
To: IRON THERAPEUTICS HOLDINGS AG
Reel/Frame 027814/0445 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2005
From: STOCKHAM, MICHAEL A.
To: VITRA PHARMACEUTICALS LIMITED
Reel/Frame 016615/0078 →
Priority Claims (1)
GB 0211500.4 · May 18, 2002 · national
Continuity (1)
Related Publication 20050250754A1 · Nov 10, 2005